Related references
Note: Only part of the references are listed.A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer
Rachel L. Stewart et al.
CANCER RESEARCH (2019)
Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression
Michael A. Brehm et al.
FASEB JOURNAL (2019)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
Caroline Jochems et al.
ONCOIMMUNOLOGY (2019)
Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies
Julius Strauss et al.
CANCER RESEARCH (2019)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Anti-PD-L1/TGFI3R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
Italia Grenga et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Karin M. Knudson et al.
ONCOIMMUNOLOGY (2018)
Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-beta and PD-L1.
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Humanized Mice for the Study of Immuno-Oncology
Philippe De La Rochere et al.
TRENDS IN IMMUNOLOGY (2018)
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
153OM7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype
C Yoo et al.
ANNALS OF ONCOLOGY (2018)
661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer
Y-J Bang et al.
ANNALS OF ONCOLOGY (2018)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Caroline Jochems et al.
ONCOTARGET (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta in advanced solid tumors.
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice
Miguel F. Sanmamed et al.
CANCER RESEARCH (2015)
Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model
Michael D. Roth et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells
S. M. Buechner et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγnull (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells
L. Covassin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
MHC class I/II deficient NOG mice are useful for analysis of human T/B cell responses for human tumor immunology research
Tomonori Yaguchi et al.
Journal for ImmunoTherapy of Cancer (2013)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype
Niwa Ali et al.
PLOS ONE (2012)
Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγnull H2-Ab1tm1Gru Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease
L. Covassin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Humanized Mice for the Study of Type 1 Diabetes and Beta Cell Function
Marie King et al.
IMMUNOLOGY OF DIABETES V: FROM BENCH TO BEDSIDE (2008)
The role of the NKG2D immunoreceptor in immune cell activation and natural killing
AM Jamieson et al.
IMMUNITY (2002)
Share Paper
